Category Archives: Genetics

Technology and Health Leaders Join Myriad Genetics, Advance in Senior Roles to Drive Key Enterprise Functions, Transformation and Growth Initiatives -…

SALT LAKE CITY, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced several new technology and healthcare leaders who recently joined the company as well as key promotions to drive critical business functions, transformation and growth initiatives.

With the addition of new leaders from other industry leading enterprises, we continue to augment our strong bench of talent across a range of functions that will accelerate the execution of our strategy with disciplined process management and proven expertise, said Paul J. Diaz, president and CEO of Myriad Genetics. We are pleased to welcome new teammates who share the passion for our mission to improve health and wellbeing for all as we continue to recruit and promote top talent from outside and inside our company.

The following Myriad Genetics leaders are assuming broader roles:

Kevin R. Haas is promoted to Chief Technology Officer, reporting directly to Diaz, responsible for engineering, data and analytics, genetic laboratory software, and improving the customer experience through tech-enabled, customer-centric commercial capabilities. Since joining Myriad in 2013, Haas has served in senior level leadership roles across research and development, bioinformatics, engineering and technology.

Faith Zaslavsky is promoted to president of Myriad Oncology which offers genetic testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs. Since 2019, Zaslavsky has served as general manager of this business unit, overseeing products including Myriad myRisk Hereditary Cancer, myChoice CDx companion diagnostic, and EndoPredict breast cancer tests. Over her 21-year career at Myriad, Zaslavsky has held progressively responsible sales, strategic account management and leadership roles.

New leaders recently joining Myriad include:

Maggie Ancona, senior vice president, Enterprise Transformation and Program Management Office. She reports directly to Diaz, managing a broad range of enterprise-wide transformation initiatives and workstreams with a focus on operational excellence. Ancona previously led Global Transformation and Program Management at Hewlett Packard (HP) and Dell Technologies where she oversaw business transformation strategy, executed large-scale programs and cost management efforts, while retooling digital infrastructure for the future.

David Hammer, senior vice president, Revenue Cycle Management, has overall accountability for the process, including functions that contribute to the capture, management, and collection of diagnostic-service revenue and related areas designed to improve the customer experience. He previously held senior revenue cycle management roles at RGP Healthcare, MedAssets, and Accenture. Hammer also serves on the Board of Advisors of the University of Florida's College of Public Health and Health Professions.

Chris Williamson, senior vice president, Information Systems and Security. Williamson previously led all facets of information technology, infrastructure, business intelligence and operations for Data2Logistics, a leading data-driven freight, audit and payment services company. A retired Naval Officer, Williamson served in the White House (executive office of the President) for the Technology Assessment Center and Information Technology Working Group.

Edward Gala, senior vice president, Enterprise Marketing Communications, responsible for strategic public relations, employee and executive communications, and overall brand marketing. Gala previously held global marketing and communications leadership positions at Xerox and Philips where he played a key role in brand transformation and positioning, business-to-business and consumer marketing across corporate, business, market and product groups.

Karen Renner, vice president, Digital Marketing, responsible for digital infrastructure, patient lead nurturing, conversion and support for products including Myriads myRisk Hereditary Cancer test and related digital initiatives across Womens Health and Oncology. Karen previously served as the global digital and eBusiness leader at Nestle Purina and brings prior digital agency experience with leading consumer product accounts at VMLY&R.

Jackie Zou, vice president, Business Development, responsible for supporting new growth opportunities, including the development and execution of transactions such as divestitures, potential mergers and acquisitions (M&A), and new partnerships. Zou held senior roles in strategy and finance, at Western Digital Corporation (WD), a global data technology, storage and digital content company, where she planned and executed merger, acquisition and divestiture transactions, joint venture initiatives, strategic partnerships and business development. Zou previously worked at Symantec, ZS Associates and Goldman Sachs.

Justin Hunter, vice president, Corporate Legal Affairs, responsible for providing legal counsel and support for corporate governance, SEC reporting, M&A, and related matters. Hunter previously served as senior legal counsel for Parsley Energy where he was responsible for SEC reporting and compliance, acquisitions and divestitures, and corporate governance. Previously he worked at Vinson & Elkins LLP and as a law clerk to Vice Chancellor Noble on the Delaware Court of Chancery.

Top Place to WorkMyriad Genetics recently was named among the Top Places to Work in Energages Top Workplaces USA list for 2021. The company ranked number one in the Health Industry category and earned additional awards in Cultural Excellence and Innovation & Leadership. Myriad employs more than 2,800 people across the United States and in several countries around the globe. To learn more about career opportunities at Myriad, visit our website.

About Myriad GeneticsMyriad Genetics Inc., is a leading genetic testing and precision medicine company dedicated to transforming patient lives worldwide. Myriad discovers and commercializes genetic tests that determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across medical specialties where critical genetic insights can significantly improve patient care and lower healthcare costs.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice CDx, Vectra, Prequel, Foresight, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor StatementThis press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to driving key business functions, transformation and growth initiatives and accelerating the execution of Myriads strategy with disciplined process management and proven expertise; and the Companys strategic directives under the caption "About Myriad Genetics." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: uncertainties associated with COVID-19, including its possible effects on our operations and the demand for our products and services; our ability to efficiently and flexibly manage our business amid uncertainties related to COVID-19; the risk that sales and profit margins of our molecular diagnostic tests and pharmaceutical and clinical services may decline; risks related to our ability to transition from our existing product portfolio to our new tests, including unexpected costs and delays; risks related to decisions or changes in governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services and any future tests and services are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities and our healthcare clinic; risks related to public concern over genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about our business, results of operations and financial condition; risks related to the potential market opportunity for our products and services; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents or other intellectual property; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Assn for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Intl, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K for the fiscal year ended June 30, 2020, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and Myriad undertakes no duty to update this information unless required by law.

Read more here:
Technology and Health Leaders Join Myriad Genetics, Advance in Senior Roles to Drive Key Enterprise Functions, Transformation and Growth Initiatives -...

People with ADHD and DBDs share genetic variants associated with risky behaviors – News-Medical.net

People with attention-deficit / hyperactivity disorder (ADHD) combined with disruptive behavior disorders (DBDs) share about 80% of genetic variants associated with aggressive and antisocial behaviors.

This is one of the conclusions of a study published in the journal Nature Communications which counts on the participation of professor Bru Cormand, from the Faculty of Biology and the Institute of Biomedicine of the University of Barcelona (IBUB), Sant Joan de Du Research Institute (IRSJD) and the Rare Diseases Networking Biomedical Research Centre (CIBERER), and researchers Marta Ribass and Josep Antoni Ramos Quiroga, from Vall d'Hebron Research Institute (VHIR) and the Mental Health Networking Biomedical Research Centre (CIBERSAM).

The study -the most ambitious one published to date on risk genetic factors shared between people with ADHD and DBDs- is based on the study conducted to about 4,000 affected people by these pathologies and 30,000 control individuals, within the frame of the European project Aggressotype, from the Horizon 2020 program, aimed at doing research on the neurobiological basis of the aggressive behavior.

The study is led by Ditte Demontis and Anders D. Brglum (Aarhus University, Denmark) and Stephen V. Faraone (State University of New York, United States).

ADHD: a psychiatric disorder that does not always come alone

ADHD is a common behavior disorder -it affects about 5% of children and 2.5% of adult people- and features hyperactivity, impulsiveness and attention deficit. This disorder usually comes with other psychiatric alterations, mainly disruptive behavior disorders (DBDs), which can be associated with antisocial and aggressive behaviors.

ADHD and DBD are caused by genetic and environmental factors. Regarding ADHD, it is estimated that genetics account for a 75%, while in DBDs, it would oscillate between 40 and 70%. These clinical pictures are more frequent in boys than girls, and when they come together, people are more likely to fall into risky behaviors, addictive substance use, and premature death."

Bru Cormand, Professor, Department of Genetics, Microbiology and Statistics and Head of the Research Group on Neurogenetics, University of Barcelona

"Certain people feature two or more psychiatric disorders, and this coexistence continues, in many cases, in a chronological axis, in which suffering from a psychiatric disorder such as ADHD involves opening the door to other comorbid pathologies that aggravate the life quality of those who suffer from the disorder", notes Marta Ribass, head of the Laboratory of Genetic Psychiatry of Vall d'Hebrn Research Institute (VHIR).

Through genome-wide association studies (GWAS), researchers analyzed the genetic contribution of changes in a single DNA nucleotide (SNP) -the most abundant ones in the human genome- to these psychiatric disorders. As part of the study, VHIR and UB experts brought samples of patients with ADHD diagnosed at Hospital Vall d'Hebron and took part in the analysis of genetic data.

The research team identified a genomic segment in chromosome 11 which increases the risk of having ADHD combined with DBD. "This region has the STIM1 gen, which is involved in the regulation of calcium cell levels, neuronal plasticity and learning memory", notes Bru Cormand, who coordinated the international working group on genetics in the Aggressotype project.

"Our study shows that genetics are more determining in people with ADHD and DBD than those who only suffer from ADHD", highlights Bru Cormand.

"If we compare the genome of patients with ADHD and DBD to that of those patients with the only ADHD, we see that people affected by both disorders have a higher genetic correlation with risk genetic variants. These extra correlations of ADHD and DBD patients would probably correspond to alterations other authors had related to aggressive-related behaviors", notes Cormand.

"If we consider ADHD to be an open door to a negative trajectory, using genetic information to identify those individuals who are more vulnerable will have a strong impact on prevention, early detection and treatment, and will shed light on new research studies to find efficient therapies that can be specific for the disorder or shared between several disorders", notes Marta Ribass.

The study, published in the journal Nature Communications, is a new science advance that will contribute to broadening the genetic landscape of ADHD comorbidities (that is, the series of pathologies that are correlated with this disorder).

From a clinical perspective, knowing the psychiatric alterations that share genetics is a step forward, because it will enable the prediction of potential secondary complications over the life of those individuals with ADHD.

"These results allow us to better understand the origins of DBDs associated with ADHD and provide better information to the family members about this disorder", concludes Josep Antoni Ramos Quiroga, head of the Psychiatry Service of Hospital Vall d'Hebron and the Research Group on Mental Health Psychiatry and Addictions at VHIR.

Source:

Journal reference:

Demontis, D., et al. (2021) Risk variants and polygenic architecture of disruptive behavior disorders in the context of attention-deficit/hyperactivity disorder. Nature Communications. doi.org/10.1038/s41467-020-20443-2.

View original post here:
People with ADHD and DBDs share genetic variants associated with risky behaviors - News-Medical.net

Honors Programs and RIETS Host a Discussion on Genetic Testing and Jewish Law Yeshiva University News – Yu News

Esti Rose

On Tuesday, February 2, 2021, the Jay and Jeanie Schottenstein Honors Program at Yeshiva College, the S. Daniel Abraham Honors Program at Stern College for Women, the Business Honors and Entrepreneurial Leadership Program at the Sy Syms School of Business, and the Rabbi Isaac Elchanan Theological Seminary(RIETS) hosted Genetic Testing: A Scientific and Halachic Perspective.

The featured speaker was Esther Rose07S, a genetics counselor from JScreen, a program for Jewish genetic diseases headquartered at Emory Universitys Department of Human Genetics. Sara Gdanski21S, a current honors student who has worked as a JScreen intern, developed the idea for the very successful event that drew approximately 200 participants.

Joining Rose was Rabbi Aryeh Lebowitz, director of the Semikhah [rabbinic ordination] Program at RIETS, and the panelists discussed scenarios involving reproductive genetic testing and how screenings might influence family planning.

The session was incredibly informative and well presented, said Yonatan Kurz23YC.Learning about the importance of genetic testing and the accompanying halachic [Jewish law] and practical implications made it a tremendously helpful and enlightening presentation.

Dr. Eliezer Schnall, director of Yeshiva Colleges Honors program, was excited by the turnout and looks forward to co-hosting more events that bring together the Universitys honors programs.

The rest is here:
Honors Programs and RIETS Host a Discussion on Genetic Testing and Jewish Law Yeshiva University News - Yu News

How two researchers built the first genetics cohort of African children with autism | Spectrum | Autism Research News – Spectrum

Maria Chahrour

Assistant professor, University of Texas Southwestern

President, Reaching Families Advocacy and Support Group

In 2015, Maria Chahrour, assistant professor of genetics and neuroscience at the University of Texas Southwestern Medical Center, began recruiting participants for studies on autism genetics out of her lab in Dallas. Among those who responded were parents and families who had recently immigrated from East Africa. They wanted to join the study, but they had some concerns and questions. So they asked if they could form their own group, in which they could help create the rules around how their data would be collected and used.

The collaboration that bloomed from those conversations created the first cohort of African children with autism one that continues to grow and recruit families around the globe. Chahrour and her research partner, Leah Seyoum-Tesfa, spoke to Spectrum about their experiences forming the cohort and why increasing genetic diversity is vital for autism research. Listen to the interview here, or read the transcript below or download it here.https://s3.amazonaws.com/spectrumnews-web-assets/wp-content/uploads/2021/02/12180920/Spectrum-interview-2.11.21.mp3

Spectrum: Could you both tell me who you are and what you do?

Maria Chahrour: Okay, well, hello, everyone, and thank you for having us. My name is Maria Chahrour. Im an assistant professor at the Eugene McDermott Center and the neuroscience department at UT Southwestern Medical Center in Dallas. My lab studies the genetics of autism. We want to find the genes that cause autism and to study their function in depth, so that we can understand the specific biological pathways that they function in. And ultimately, we hope that our work will inform diagnosis and therapies.

Leah Seyoum-Tesfa: My name is Leah Seyoum-Tesfa. Im originally from Ethiopia. I live in Irving, Texas. I am a mother of four children, two of whom are on the autism spectrum. In 2011, I started a nonprofit organization called Reaching Families Advocacy and Support Group. The purpose of the organization is to work with East African families who have children with intellectual and developmental disabilities. The organization started in Dallas, Texas, but its spread to we have several organizations all over the United States. By training, Im a nurse and I was a nurse practitioner. But I work, currently Im an advocate. I support families in various systems in the medical, educational, as well as the social systems. I also provide community awareness about developmental disabilities all over the United States.

I enjoy working with families; its a very rewarding thing to be able to support families access [to] early intervention and see the progress that children made throughout the year. And I support families also and their children to adulthood.

S: Thank you both for joining us, and you both do really interesting work, so Im excited to talk about how you work together. Could you tell me a little bit about how you first met each other and came to work together?

MC: Sure. So in 2015 I moved to Dallas to start my own lab. And, as I said, a big part of our mission is to identify causative genes in families with autism with a specific focus on Dallas diverse population. So I had an ongoing human genetics study, recruiting local families with autism, and someone from the Ethiopian community in Dallas found out about the study. He actually works at UT Southwestern as well, and he saw one of our flyers and told Leah about the study, and then he introduced us. And I guess, Leah, I would love to hear how that initial reach-out happened for you and what was your impression when you heard about the study?

LS-T: When Dr. Bogale [Aredo], who was the president of [the Ethiopian Health Professionals Association] I am a member of that group reminded me about this study, and he saw the flyer and he showed it to me, I was very interested, because Ive been concerned about the number of children that I see that have, from the East African community, primarily with autism. Ive felt for a while that we are seeing a higher prevalence in our population. And we also see more-affected children in our population. So when he showed me the flyer, I was very interested because our community wants to find out why the higher prevalence and if theres a genetic connection in our community. So I contacted Maria, and our collaboration started from there.

S: How did you come to collaborate rather than just participating in the study? Did you initially set out to want to have a bigger role in the study, or how did that relationship come about?

MC: I was really interested and impressed with everything that Leah had been doing and all of her efforts in her community. And you know, we had all these discussions about what she found with the higher prevalence of autism in East African families as she was working with the community. And we started having more and more of these meetings and discussions, and it sort of organically, I guess, grew into a collaboration. It was, I would say, a mutual learning journey for both of us, you know? I was really fascinated with all of the aspects that she was an expert in. And vice versa, I think.

LS-T: I agree with that. Yeah, it was a learning experience for me as well. Because other than the research that I have done as part of my training at the LEND program I had attended a training in 2013, and my project was on the prevalence of autism in the East African community in Texas. I had taken data from the Texas Education Agency, and I had found that it was a higher prevalence. And this came when I met Maria; I was very interested in studying this further.

S: I think Maria had told me previously that once you wanted to include more people from your community in the study, that there were some questions that came up about participating, and it actually spawned its own separate cohort study instead. Can you tell me about some of those questions that came up? And then how that led to a separate study being made for the African community around autism?

MC: So, as I mentioned, you know, the two of us started meeting and discussing the study designs and what elements we had to take into consideration. So, specifically, the communitys concerns about privacy and data protection and the stigma associated with autism within the community. I visited the community center and church multiple times, spoke to family members about autism and genetics, and about the study that we were running. And, you know, myself and Leah, we answered their questions and addressed their concerns. And I would say, then, we took care of some logistics. Before I go into that maybe Ill let Leah tell you a little bit more about the families specific concerns around these issues.

LS-T: Theres a lot of stigma around it. And people are very careful to admit their children have autism, or a family member. Unfortunately, its associated with mental health issues, and somebody being crazy, or somebody being like an evil spirit. So the stigma around it was a big issue that we have to deal with, and I still deal with in the community. The other concern was lack of knowledge. They didnt know what research would mean. Its not something that weve participated [in] as a community in the DFW area, or even any area that Im aware of as an immigrant community. So doing a study was something new.

S: And DFW, is that Dallas-Fort Worth?

LS-T: Dallas-Fort Worth, Im sorry.

The other piece was, what is going to come with this study? Whats the outcome and what the data was going to be used for?

S: And so, what kind of things did you do, both in the recruiting and in the study design, to kind of allay those concerns?

MC: I would say we really had a lot of discussions. A critical part of this was just meeting with family members, addressing all of their questions, making sure that everyone is comfortable with everything we had in the study forms. Leah had reviewed all of the study forms. And we translated them into Amharic and Tigrinya. And then after we finalized all of these logistics, Leah announced the start of recruitment and enrollment to the community members and the families that she was supporting through the Reach foundation. I would say it took us about two years from when we initially met, to set everything up and have all of these really important and critical discussions with community members so that we can incorporate their feedback, before we actually started actively enrolling participants.

S: Wow, two years. Thats a long time.

MC: Yeah.

S: And so what has the recruitment process been like since then? You know, how many families have you been able to recruit and is it still ongoing? Catch me up to how its been going the last couple of years.

MC: This past year, its been really slow, of course, with everything thats going on with the COVID-19 pandemic. But you know, so far weve enrolled 30 families, I would say, and thats over 120 individuals, and its still very much ongoing and active.

When UT Southwestern shut down earlier in March, human subject research that did not involve a critical procedure was kind of put on hold. So we couldnt bring in study participants for their research appointments. I think that was the main hit. But now, you know, were hoping that things are going to get better, and that were able to deal with all of these logistical issues. Were all adapting, I would say.

S: So, Leah, you told us at the beginning about what Reach does. Can you tell me how that plays a role in the study that you do with Maria?

LS-T: I work by bringing community awareness. I go to several churches before COVID. Now through Zoom, I do community awareness; I teach families about early signs of autism. And the purpose is to get early intervention. At that time, I do offer all the families an opportunity to participate in the study. And not all families are ready to do that. Theyre still trying to accept that their child has autism. Were also going through the difficult diagnostic process, finding a diagnostician and waiting on these long lines with the various providers. So it takes a little bit longer. I think within a year after the diagnosis, a lot of families will agree or decide to participate or not.

So the purpose, as I said, is to provide early intervention and help families, but as part of that I do explain to them about the research and the opportunity to join the research. Like I said, its not every family that chooses to participate. But some families are very interested; some choose to just do a genetic study through their pediatrician or specialist. But thats how we are able to reach families. Now I do have like I said, I started with families in [the] Dallas area but I do have families, we even have some families in Europe, that live in Germany and I think other countries, that were able to participate in this study.

S: Wow. Do you have partners in Europe that sort of help with the recruitment there?

LS-T: No, I do 100 percent of the recruitment, families that I support through accessing interventions. We do have a heavy online presence, and through our website, and through our Facebook and other resources, we provide information. We have monthly educational meetings that are available to any families recorded. We teach them about various things about early intervention, about therapies, about [applied behavior analysis], about all kinds of things, dietary interventions. We have specialists that come and speak to families about, the bigger one is a lot of behavior support. Fortunately, we do have many community members that are in the profession that are able to share this information in Tigrinya and in Amharic that is very accessible to these families. So families from all over the world, we have families in Africa as well, in Asia; people, immigrants, families can access our educational information. And part of that educational information is we had Maria speak about the genetic study, and they can access that and reach Maria at UT Southwestern to participate in the study.

MC: Once we make contact with the families, you know, my study coordinator sort of arranges for the research appointment if theyre local, or otherwise we send them a study kit with instructions of what to do and how to actually collect samples and things like that.

S: And when youre doing this global outreach, are you mostly focused on families from Ethiopia specifically?

MC: So were focusing on East African families, specifically from Ethiopia and Eritrea, although weve had Kenyan and Somali families participate as well. But the vast majority are from Ethiopia and Eritrea.

LS-T: We do support, actually, Kenyan families. Theres not a heavy presence in the DFW area. But we do have a mother that supports the Kenyan families, and through her we were able to recruit a few families I believe, but its heavy Ethiopian, Eritrean immigrant families in the DFW area.

S: And you have a partner in Ethiopia, correct? An organization there that you partner with?

MC: It sort of started as this part of our long-term capacity-building project for autism in Ethiopia. So I got to visit the Joy Autism Center in Addis Ababa in the summer of 2019. And I discussed our study with the center founder, Zemi Yenus. And as part of that trip, I also gave a talk and ran a workshop with colleagues on autism and autism genetics at the Bahir Dar University, and that was geared towards healthcare professionals. So Zemi is interested in collaborating with myself and Leah, but we havent actually started enrolling participants simply because of logistical issues that were caused by the pandemic and the recent political unrest. Of course, we are planning to expand our study and collaborate with colleagues and community partners in Ethiopia. Thats our long-term plan.

S: And so now that its been going on, the studys been going on for a few years, what have you been hearing from families about their experience participating in the study?

MC: I believe theyre excited about the study. Weve had a meeting after we completed the latest batch of sequencing to discuss our preliminary analysis with the community. And were planning for other community update meetings as we finalize our analysis. But I think Leah can speak more to the familys impressions and how motivated they are to participate.

LS-T: The ones that have participated are very eager to know the results. They call me often and say, What have we found? Where are we now? Theyre just eager to find out; the process was very easy. Maria really made it easy in that the kit was sent home; when we were drawing blood, the phlebotomist came to the home to draw the blood. And it was really a very smooth process for a lot of the families, even the ones in Europe. They told me the process was very easy. And were just waiting for the results. Everybodys eager. We are realizing the prevalence; were seeing a lot of our friends and siblings also having children with autism. So thats what we really need to know, if there is a genetic connection here.

S: Im curious if youve seen any kind of shifts, like you mentioned that theres some stigma in the community or just not being as familiar with research studies. Have you seen, anecdotally, shifts from people who have participated in any of those attitudes?

LS-T: You know, I see a change in that even families that have not participated in the study are now very interested in doing that. Initially, people were worried about whats going to happen with the data is my name is going to be available on [the] internet about my child having autism? those kinds of concerns. But now that they know, and Maria has come and explained to us how the data is saved, there are more families interested. Because of COVID, theres a lot going on with the disability community. COVID has been even harder. Families are struggling with kids not attending school. So its kind of been really hard. And then finding even somebody to diagnose the children during this time has been difficult.

But Ive seen a shift. Ive seen a shift in stigma, because theres so many of us, many centers all over the United States, that we are going to the churches and talking about autism. Were in a good place; I think were going in the right direction. Kids are getting help sooner.

S: It sounds like a really powerful community-based approach to doing this kind of science.

MC: Yes, yes, for sure.

LS-T: Definitely. Definitely.

S: And maybe we can talk a little bit about, you know, what youre finding from the study. What kind of gaps is that filling for the science about autism?

MC: Populations in Africa are the most genetically diverse in the world and carry up to three times as many rare variants as, say, populations of European origin. And research so far on the genetics of autism has overwhelmingly focused on people of European ancestry. And, of course, although these studies are extremely valuable to our understanding of this complex genetics of autism, they dont really capture the genetic diversity on the African continent. And this loss of genetic diversity in the current studies really limits our scope of understanding autism.

So because genomic studies so far have been largely focused on European populations and identifying autism variants in these European cohorts, the transferability of these findings to non-European populations is limited.

And then, of course, as genetic findings move into the clinic, this lack of diversity and lack of genetic data from non-European populations translates to healthcare disparities. So when a genetic diagnosis is made in the clinic, its vital to understand the variant in the context of ancestry, because the frequencies of some of these variants are population-specific.

So for clinical genetics to be equitable, it needs to be able to offer patients and their families interpretation that encompasses their specific ancestry. And as a genetics community, the community as a whole recognizes this need for diversity and the need to do more sequencing on the African continent to be able to understand variants in the context of ancestry, and is working to be more inclusive. An example of this, you know, theres a big effort right now thats focused on exactly doing this. And its the Human Heredity and Health in Africa, or the H3Africa consortium, which was conceived to address the paucity of genomics research in Africa. So I think we have a lot to learn from this. We have a lot to find and discover. And we have this amazing opportunity to do this now.

LS-T: We realize theres a very heavy burden of more affected children in our community. I strongly believe in that. Were seeing more kids in our community. Siblings I have a lot of families that have two, three children somewhere on the spectrum. I myself have two kids on the autism spectrum, fraternal twins. So we are very eager to find out what is causing this high incidence of autism in our children. And hopefully, this research will answer some of our questions.

MC: I just want to add to that we are really interested and we set out to see: What is this genetic factor thats predisposing the community to autism? And thats sort of the big question that were going after.

S: When you say theres a higher prevalence in the community, what kind of numbers would you say there are?

MC: Leahs own work on public schools in the state of Texas showed that the prevalence is up to three times higher than the prevalence in the general non-African population. And also, there is one of the sites where the [Centers for Disease Control and Prevention] does the monitoring network for autism is in Minnesota, and they found that the prevalence of autism in the Somali population in Minnesota was, I believe, up to two to three times higher than the general population as well.

So there are all these findings that were pretty much from prevalence studies that were done on immigrant populations outside of Africa because, unfortunately, I believe there are only two prevalence studies for autism in Africa one out of Uganda and one out of Nigeria. You know, of course, depending on who you ask, there might be other factors that influence or result in this higher prevalence. And of course, these prevalence studies on immigrant populations are smaller than what you would typically see from other prevalence studies. But we think its a start. We think that in the meantime, we can do something with the information that we already have. And you know, as a geneticist, Im really interested in the genetic risk factors. Although were not eliminating other hypotheses, of course, but were testing our hypothesis that there is a genetic risk factor in this community

LS-T: And the study that I did, it wasnt published, but it was part of my report. In the Amharic-speaking population, we saw 1 in 40. In the Tigrinya-speaking, we saw 1 in 51. And in the Ethiopic they call it Ethiopic because theres other languages spoken in Ethiopia, including Amharic, Tigrinya, Oromo 1 in 22 children had autism.

And then in the whole Texas population, at that time is 1 in 167 children were identified educational identification of autism, with my research. And then, as Maria mentioned, we reviewed a lot of studies that were done in Europe. And theres also a study out of California that showed higher prevalence in immigrant families who have children with autism who are African American. The European studies looked in depth about East African families. There was also a New Zealand and Australian study that had higher prevalence in our community.

S: Wow, those are some very big discrepancies. Very big differences.

LS-T: There was, there was. And you know, the other thing is, this is in educationally identified children. They were looking at the children that are, they tend to identify the more affected children. And the kids that are less affected are not identified, even so in our community, because parents dont want their children identified. If theres a little bit of, you know, social problems, and the kids end up being verbal, they usually dont want their kids identified. These are kids that have significant disability and are often educated separately in a self-contained classroom.

So were looking at even a much higher rate in our community, because were not always identifying all the children. This was, if you look at the Somali study in Minnesota, the first study came out in 2014. Those identified were 100 percent of those children had intellectual disability. Whereas a much lesser number of children in the Minnesota study of the other races had intellectual disability. What that tells me, and I think the researchers concluded, is that were not identifying those kids that are less affected in these communities. Were just looking at those with intellectual disability that are easily identified in the school system.

MC: Yeah, yeah. So, you know, basically, were missing a lot of kids who are more mildly affected. And I think that, again, speaks to this really big need for doing comprehensive prevalence studies in Africa.

LS-T: Definitely, definitely.

S: And does your genetic study mostly then lean toward having people who have intellectual disability? Or are you also working to identify those less affected kids and get them in the study as well?

MC: So we do have kids on both ends of the spectrum, I would say. Its because these families were primarily identified through Leahs efforts in the Reach foundation, and she works with all kinds of kids on the spectrum. So, you know, we are enrolling everyone at this point, yeah.

LS-T: We do have the same, even people, families that come to me for help, usually have more affected children. These kids are identified early on; usually theyre all over the spectrum. But the older kids that are identified usually are more significantly affected that come to me for help.

S: So just thinking about the more broad need in the field to have greater diversity in genetic studies, are there any kind of lessons that you think youve learned in creating and working on this cohort that might inform other researchers about how to increase diversity in genetic studies?

MC: Yes, this is a big question. And we could both go on and on. So we certainly learned a lot. For one, we need to continue doing this and expand our study to enroll more participants and sequence more genomes. And the genetic diversity on the African continent can teach us a lot about the genetics of autism and about the biological pathways and mechanisms underlying the disorder.

We learned that theres still a lot of stigma associated with having autism in many communities. And we need to really be diligent about removing that stigma and spreading the right information so that we can empower families to deal with this in their communities. And we need to listen to, understand and respect the communities concerns. And we need to work together. It has to be a true partnership between scientists and parents for us to be successful. We also learned that a lot of these families are facing and dealing with the burdens of autism without much support. So participating in research studies may not necessarily be a top priority when you dont have access to basic services.

LS-T: Yeah. You said it really well, Maria. Families are struggling, caring for the kids and accessing resources. Sometimes research is not a priority for them. I think the fact that Maria was able to come and explain everything really well for us, that was very helpful. And she also had an opportunity to come back and update us about where the research is. And we were able to recruit more families after that.

I think just understanding their culture and the stigma around it was very good for Maria to understand and work with us [and make] research easy for the families. She accommodated the needs of the families, because it would have been very hard for the families to take their kids to have their blood drawn, the whole family; she made that very easier. And those things are very important. Making things very accessible for the families and continuing to communicate with them. Its very important, especially for communities that are not, might not have a lot of knowledge about research.

S: Great. Well, this has been a really fascinating discussion about your work. Im really curious to see where it goes in the next couple of years.

MC: Thank you. Yeah, were both really excited about this, and hopeful.

LS-T: And thank you for giving us the opportunity to share our research and about our concern in our community.

Continue reading here:
How two researchers built the first genetics cohort of African children with autism | Spectrum | Autism Research News - Spectrum

Genetic study of Lewy body dementia supports ties to Alzheimer’s and Parkinson’s diseases – National Institutes of Health

News Release

Tuesday, February 16, 2021

NIH-led study locates five genes that may play a critical role in Lewy body dementia.

In a study led by National Institutes of Health researchers, scientists found that five genes may play a critical role in determining whether a person will suffer from Lewy body dementia, a devastating disorder that riddles the brain with clumps of abnormal protein deposits called Lewy bodies. Lewy bodies are also a hallmark of Parkinsons disease. The results, published in Nature Genetics, not only supported the diseases ties to Parkinsons disease but also suggested that people who have Lewy body dementia may share similar genetic profiles to those who have Alzheimers disease.

Lewy body dementia is a devastating brain disorder for which we have no effective treatments. Patients often appear to suffer the worst of both Alzheimers and Parkinsons diseases. Our results support the idea that this may be because Lewy body dementia is caused by a spectrum of problems that can be seen in both disorders, said Sonja Scholz, M.D., Ph.D., investigator at the NIHs National Institute of Neurological Disorders and Stroke (NINDS) and the senior author of the study. We hope that these results will act as a blueprint for understanding the disease and developing new treatments.

The study was led by Dr. Scholzs team and researchers in the lab of Bryan J. Traynor, M.D., Ph.D., senior investigator at the NIHs National Institute on Aging (NIA).

Lewy body dementia usually affects people over 65 years old. Early signs of the disease include hallucinations, mood swings, and problems with thinking, movements, and sleep. Patients who initially have cognitive and behavioral problems are usually diagnosed as having dementia with Lewy bodies, but are sometimes mistakenly diagnosed with Alzheimers disease. Alternatively, many patients, that are initially diagnosed with Parkinsons disease, may eventually have difficulties with thinking and mood caused by Lewy body dementia. In both cases, as the disease worsens, patients become severely disabled and may die within eight years of diagnosis.

A growing body of evidence suggests genetics may play a role in the disorder and that some cases may be inherited. Scientists have found that some of these rare cases can be caused by mutations in the gene for alpha-synuclein (SNCA), the main protein found in Lewy bodies. Further studies have found that variants in the gene for apolipoprotein E (APOE), which is known to play a role in Alzheimers disease, may also play one in Lewy body dementia.

Compared to other neurodegenerative disorders, very little is known about the genetic forces behind Lewy body dementia, said Dr. Traynor. To get a better understanding we wanted to study the genetic architecture of Lewy body dementia.

To do this, they compared the chromosomal DNA sequences of 2,981 Lewy body dementia patients with those of 4,931 healthy, age-matched control participants. Samples were collected from participants of European ancestry at 44 sites: 17 in Europe and 27 across North America. The DNA sequencing was led by Clifton Dalgard, Ph.D., and researchers at The American Genome Center, a series of state-of-the-art laboratories at the Uniformed Services University of the Health Sciences and supported by the Henry M. Jackson Foundation for the Advancement of Military Medicine.

Initially, they found that the sequences of five genes from the Lewy body dementia patients were often different from those of the controls, suggesting that these genes may be important. It was the first time that two of the genes, called BIN1 and TMEM175, had been implicated in the disease. These genes may also have ties to Alzheimers and Parkinsons diseases. The other three genes, SNCA, APOE, and GBA, had been implicated in previous studies, and thus, strengthened the importance of the genes in Lewy body dementia.

The researchers also saw differences in the same five genes when they compared the DNA sequences of another 970 Lewy body dementia patients with a new set of 8,928 control subjects, confirming their initial results.

Further analysis suggested that changes in the activity of these genes may lead to dementia and that the GBA gene may have a particularly strong influence on the disease. The gene encodes instructions for beta-glucosylceramidase, a protein that helps a cells recycling system break down sugary fats. The researchers found that both common and rare variants in the GBA gene are tied to Lewy body dementia.

These results provide a list of five genes that we strongly suspect play a role in Lewy body dementia, said Dr. Traynor.

Finally, to examine the apparent links between Lewy body dementia and other neurodegenerative diseases, the researchers further analyzed data from previous studies on Alzheimers and Parkinsons disease. They found that the genetic profiles of the patients in this study had higher chances of suffering from either Alzheimers or Parkinsons disease than the age-matched control subjects. These predictions held even after they lowered the potential impact of known Alzheimers and Parkinsons disease-causing genes, like APOE and SNCA. Interestingly, the patients genetic risk profiles for Alzheimers disease, on the one hand, or Parkinsons disease, on the other, did not overlap.

Although Alzheimers and Parkinsons disease are molecularly and clinically very different disorders, our results support the idea that the problems that cause those diseases may also happen in Lewy body dementia, said Dr. Scholz. The challenge we face in treating these patients is determining which specific problems are causing the dementia. We hope studies like this one will help doctors find precise treatments for each patients condition.

To help with this effort, the team published the genome sequence data from the study on the database of Genotypes and Phenotypes (dbGaP), a National Library of Medicine website that researchers can freely search for new insights into the causes of Lewy body dementia and other disorders.

Article:

Chia, R., et al. Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into the complex genetic architecture. Nature Genetics, February 15, 2021 DOI: 10.1038/s41588-021-00785-3

This study was supported in part by the NIH Intramural Research Programs at the National Institute of Neurological Disorders and Stroke (NS003154) and the National Institute on Aging (AG000935).

NINDS (https://www.ninds.nih.gov) is the nations leading funder of research on the brain and nervous system.The mission of NINDS is to seek fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease.

About the National Institute on Aging (NIA): NIA leads the U.S. federal government effort to conduct and support research on aging and the health and well-being of older people. Visit the NIA website for information about a range of aging topics inEnglishandSpanish. Learn more about age-related cognitive change and neurodegenerative diseases via its Alzheimer's and related Dementias Education and Referral (ADEAR) Center website. Stay connected with NIA!

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

###

Follow this link:
Genetic study of Lewy body dementia supports ties to Alzheimer's and Parkinson's diseases - National Institutes of Health

BioIQ Partners with Fulgent Genetics to Bring COVID-19 Variant Detection to COVID-19 Testing Programs – Yahoo Finance

The groundbreaking viral genome sequencing and reflex testing solution identifies various COVID-19 variant strains, enabling employers, health plans, and public health agencies to optimize surveillance, treatment and vaccination protocol to mitigate spread of the virus more effectively.

BioIQ, an analytics-driven population health engagement and testing platform company for top employers and health plans, announces a partnership with Fulgent Genetics, Inc. (NASDAQ: FLGT), a technology company providing comprehensive testing solutions, to offer viral genome sequencing capable of identifying various variants of the COVID-19 virus.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210216005842/en/

Fulgent Genetics full viral genome sequencing is a new and rapidly evolving tool that better characterizes COVID-19 infections and the consequences of new variants in the population. The partnership makes it possible for BioIQ employer, government, and health plan customers to leverage Fulgent Genetics testing solution to inform testing regimens, clinical treatment protocols and vaccination strategies pursuant to the identified COVID-19 variant. Local public health agencies can similarly leverage the testing solution in ongoing population infection surveillance programs with BioIQ.

"With new COVID-19 variants emerging around the globe, there is growing concern that higher infectivity in some strains may result in faster spread of the virus," noted Justin Bellante, BioIQ Founder, President, and COO. "This tool will be an important addition in the diagnostic armamentarium against COVID-19 by enabling BioIQ and its customers to more rapidly identify and quarantine individuals in cases where more infectious variants are present."

"Fulgent Genetics full viral genome sequencing offering for COVID-19 leverages our capabilities in Next Generation Sequencing and represents the next evolution in COVID-19 diagnostics, complementing our extensive RT-PCR based tests for the virus," said Dr. Harry Gao, Chief Scientific Officer of Fulgent Genetics. "Some variants spread faster than others, warranting a more rigorous testing protocol in populations where that strain is identified. COVID-19 vaccine effectiveness is also dependent on the virus variant. Identification of specific COVID-19 variants will enable BioIQ and its customers to implement the most effective plan of action for responding to and mitigating the spread of COVID-19."

Story continues

"The addition of Fulgent Genetics variant testing solution to BioIQs COVID-19 testing framework brings unparalleled triage intelligence to testing efforts," said Sean Slovenski, BioIQ CEO. "We remain committed to integrating the latest, cutting-edge advancements in COVID-19 diagnostics into our testing ecosystem to support the most effective and responsible response to the pandemic through best-practice population health protocol."

Addition of the Fulgent variant test to the BioIQ digital diagnostic testing ecosystem is the latest announcement in an ever-growing lineup of resources designed to help employers, health plans, and public health agencies respond to the COVID-19 epidemic. Since the onset of the pandemic, BioIQ has continuously brought cutting-edge COVID-19 testing solutions to market. From saliva-based tests; to combined COVID-19 and flu panel tests; to mobile, on-site testing; and now variant detection; the company continues to lead the market in COVID-19 diagnostics and program management solutions.

BioIQs COVID-19 and infectious disease platform encompasses on-site, retail, and home self-collection workflows across a variety of test types within a consumer friendly, digital experience. The BioIQ framework helps employers, health plans, and local public health agencies gain access to a national network of testing options; implement convenient, analytics-driven programs to efficiently facilitate testing; and monitor and manage the patient testing journey from end-to-end.

To learn more about BioIQs COVID-19 testing programs and solutions, as well as other services to protect workforces and communities, visit http://www.bioiq.com.

About BioIQ

BioIQ is modernizing the diagnostic testing industry through a national network of labs and customized solutions that support payors, employers, and consumers. By aggregating testing solutions, optimizing lab capacity, and integrating testing with customers needs and strategies, BioIQ ensures resilience and reliability so that employers and payors can protect workforces and members. With its first-of-its-kind health connectivity platform, BioIQ is uniquely positioned at the convergence of population health and the consumerization and retailization of healthcare to drive the shift to value-based care for payers and employers. Since 2005, BioIQ has launched thousands of successful health testing programs serving millions of participants. For more information, visit http://www.bioiq.com.

About Fulgent Genetics

Fulgent Genetics proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining next generation sequencing ("NGS") with its technology platform, the company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. Since March 2020, the company has commercially launched several tests for the detection of SARS-CoV-2, the virus that causes the novel coronavirus ("COVID-19"), including NGS and reverse transcription polymerase chain reaction ("RT-PCR") based tests. A cornerstone of the companys business is its ability to provide expansive options and flexibility for all clients unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated lab services.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210216005842/en/

Contacts

BioIQ Contact: Judson PhillipsVP Marketing805-504-8586 x 7jphillips@bioiq.com

More:
BioIQ Partners with Fulgent Genetics to Bring COVID-19 Variant Detection to COVID-19 Testing Programs - Yahoo Finance

Massive National Health Study Looks to Tailor Your Diet to Your Genetic Makeup – Singularity Hub

Like taxes and death, nutrition is something we cant escape. Eating should be easy. Yet its also massively confusing, prone to misinformation, and utterly personal.

Take competitive eaters who regularly chow down on thousands of calories without gaining weight. Compare them to people who pack on pounds just looking at a French fry. Or compare people who can tolerate any food to those who are sensitive or allergic to entire food groups. Or people who thrive on a high-fat diet like keto, to unfortunate souls whowith the same dietneed to stay close to the bathroom.

You get the idea: no one diet fits all. Yet nutrition science has long relied on averages to make dietary recommendations. From the 80s fat is bad paradigm to todays sugar is horrible trend, its always been easy to vilify one food component, without digging into how each of us interact with the foodstuff we eat.

Now, thanks to a massive new project led by the National Institutes of Health (NIH), nutrition science is about to get the precision treatment. With a price tag of $156 million, the five-year-long study will examine how 10,000 Americans process food. The program, Nutrition for Precision Health, isnt pulling punches. Each person will be given a highly controlled diet to reduce variability. Theyll then be thoroughly monitored for everything from blood sugar levels to their genes, proteins, and gut microbiome composition. Using the massive dataset, the program can then develop AI-based algorithms to predict individual responses to foods and diets.

If successful, we may soon have a scientifically-proven way of optimizing our diet and health based on our genes and gut microbes. While the culinary astronauts among us may cringe at the idea, for those with metabolic disorders or food intolerances, the algorithms are a powerful tool to aid nutritionists in prescribing diets to those who seek help.

Nutrition science has had a bit of a fuzzy reputation. But its not through any fault of its own. The field faces two major unenviable challenges: one, the results are the average of entire study populations, and two, humans hate sticking to a strict diet for long enough to get consistent results. Ever tried a 14-day diet? Now imagine doing it for five years.

As Paul Coates, vice president of the American Society of Nutrition puts it, were all free-range eaters, which mucks up the resulting data.

Thats not to say classic nutrition science hasnt had major wins. Take the Framingham Heart Study, which launched in 1948 with over 5,000 people to better understand heart and blood vessel health. The study was a first population-level triumph in linking diet to cardiovascular diseases, which remains one of the top killers today.

But to NIHs director Dr. Francis Collins, its high time to bring nutrition science into the 21st century. In May 2020, the agency released a 10-year plan to dig into the nitty-gritty of nutrition, tackling the what, when, why, and how to eat to optimize health and reduce chronic health plagues such as diabetes, obesity, and heart disease.

Its looking to be a wild ride. For example, the ambitious effort doesnt just focus on the gut. Thanks to new research showing intimate connection between the gut and the braindubbed the gut-brain connectionthe plan also embraces neuroscience as a component. Given the link between longevity and diet, itll also study the role of nutrition across our lifespans, or even how to use food as medicine.

And underlying all these fundamental questions? Personalization: how each of us responds to the food we eat.

The new program will be housed under the NIHs flagship health project, All of Us. The research program aims to recruit one million people under its banner to build a Google Earth-style database of biology, health, lifestyle, and disease. The key is individuality: forget average treatments, personalization is the future.

To Dr. Griffin Rodgers, director of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDKK), now is the perfect time to explore precision nutrition. In a presentation last September, he laid out why. Were beginning to understand how the microbiome influences health. We can rapidly perform multi-omics studiesthat is, look at a persons whole system of genes, proteins, and metabolism. AI and machine learning make it easier to analyze these massive datasets. Finally, digital health tech, offered through smartphones or smartwatches, makes everyday health tracking simple and affordable.

The project is planned in three stages. Roughly 10,000 volunteers from All of Us will wear various monitorssimilar to Fitbitsto track their usual diets, physical activity, and blood sugar levels, creating a baseline. In the second stage, a subset of participants will regularly visit a clinic. There, theyll be given a controlled, specific meal, and be monitored for a series of biomarkers such as how their blood sugar levels change.

Another subset of volunteers will be given three different types of diets, one following another with a washout perioda breakin between. The prepared study foods will be eaten at home, so the participants can go about their daily lives.

Finally, up to 1,000 volunteers will stay at a clinic for three two-week-long holidays. Here, their three meals will be strictly controlled, and outside food not allowed. While seemingly harsh, going from free range to controlled is the gold standard for nutrition science, because it weeds out other variables.

While on the diet, all three groups will undergo a series of clinical tests, ranging from genetics and microbiome composition to blood sugar levels, metabolism, and urine. Psychology and behavior measures will also be assessed. Further on the docket are socioeconomic factors, such as zip code.

With these comprehensive measures, we are removing a lot of that noise that we had for years, created by the factors that we were not measuring before, said Dr. Jos Ordovs, a nutrition scientist at Tufts University.

As the study gathers data, on the back end, software engineers will begin building an infrastructure for storing, organizing, and searching the datasets. This library of data is then passed on to AI scientists to create models and algorithms that predict a persons individual response to a diet. Finally, another five-year period will validate those models in clinical trials.

Its not the first time a study has linked precision nutrition with AI. In 2015, an Israeli study of 800 people monitored their blood sugar levels and microbiome to parse out how individuals respond to different types of sugar intake. Using machine learning, the study built a software program to predict diets best suited for someone who is diabetic or hoping to lose weight.

But Nutrition for Precision Health is larger and far more sweeping than anything previously attempted. For now, the program is still at the planning stage, with a full launch expected in early 2023.

To Rodgers, the study isnt just about generating a wealth of data to fuel discovery science for years to come. The resulting tools, methods, and paradigm shift will have the potential to truly transform the field of nutrition science, he said.

Image Credit: bestbrk/Shutterstock.com

More here:
Massive National Health Study Looks to Tailor Your Diet to Your Genetic Makeup - Singularity Hub

Genetic variant inherited from Neanderthals associated with protection against severe COVID-19 – News-Medical.Net

SARS-CoV-2, the virus that causes COVID-19, impacts people in different ways after infection. Some experience only mild or no symptoms at all while others become sick enough to require hospitalization and may develop respiratory failure and die.

Now, researchers at the Okinawa Institute of Science and Technology Graduate University (OIST) in Japan and the Max Planck Institute for Evolutionary Biology in Germany have found that a group of genes that reduces the risk of a person becoming seriously ill with COVID-19 by around 20% is inherited from Neanderthals.

Of course, other factors such as advanced age or underlying conditions such as diabetes have a significant impact on how ill an infected individual may become. But genetic factors also play an important role and some of these have been contributed to present-day people by Neanderthals."

Professor Svante Pbo, Human Evolutionary Genomics Unit, OIST

Last year, Professor Svante Pbo and his colleague Professor Hugo Zeberg reported in Nature that the greatest genetic risk factor so far identified, doubling the risk to develop severe COVID-19 when infected by the virus, had been inherited from Neanderthals.

Their latest research builds on a new study, published in December last year from the Genetics of Mortality in Critical Care (GenOMICC) consortium in the UK, which collected genome sequences of 2,244 people who developed severe COVID-19. This UK study pinpointed additional genetic regions on four chromosomes that impact how individuals respond to the virus.

Now, in a study published today in PNAS, Professor Pbo and Professor Zeberg show that one of the newly identified regions carries a variant that is almost identical to those found in three Neanderthals - a ~50,000-year-old Neanderthal from Croatia, and two Neanderthals, one around 70,000 years old and the other around 120,000 years old, from Southern Siberia.

Surprisingly, this second genetic factor influences COVID-19 outcomes in the opposite direction to the first genetic factor, providing protection rather than increasing the risk to develop severe COVID-19. The variant is located on chromosome 12 and reduces the risk that an individual will require intensive care after infection by about 22%.

"It's quite amazing that despite Neanderthals becoming extinct around 40,000 years ago, their immune system still influences us in both positive and negative ways today," said Professor Pbo.

To try to understand how this variant affects COVID-19 outcomes, the research team took a closer look at the genes located in this region. They found that three genes in this region, called OAS, code for enzymes that are produced upon viral infection and in turn activate other enzymes that degrade viral genomes in infected cells.

"It seems that the enzymes encoded by the Neanderthal variant are more efficient, reducing the chance of severe consequences to SARS-CoV-2 infections," Professor Pbo explained.

The researchers also studied how the newly discovered Neanderthal-like genetic variants changed in frequency after ending up in modern humans some 60,000 years ago.

To do this, they used genomic information retrieved by different research groups from thousands of human skeletons of varying ages.

They found that the variant increased in frequency after the last Ice Age and then increased in frequency again during the past millennium. As a result, today it occurs in about half of people living outside Africa and in around 30% of people in Japan. In contrast, the researchers previously found that the major risk variant inherited from Neanderthals is almost absent in Japan.

"The rise in the frequency of this protective Neanderthal variant suggests that it may have been beneficial also in the past, maybe during other disease outbreaks caused by RNA viruses," said Professor Pbo.

Source:

Journal reference:

Zeberg, H & Pbo, S (2021) A genomic region associated with protection against severe COVID-19 is inherited from Neandertals. PNAS. doi.org/10.1073/pnas.2026309118.

More:
Genetic variant inherited from Neanderthals associated with protection against severe COVID-19 - News-Medical.Net

Genetic ancestry linked to diabetes, heart failure and obesity among Native Hawaiians | Keck School of Medicine of USC – USC News

First-ever large-scale genetic study examining Hawaiian Polynesians and health risk is led by the Keck School of Medicine of USC

(Photo/iStock)

By Wayne Lewis

With advances in analyzing human DNA, some well-studied populations have benefited from insights about how their health is affected by their genetics. Others, however, have been left behind. Among them are people of Polynesian descent from Hawaii.

Although population studies of Native Hawaiians have shown a substantial increase in risk for obesity, type2 diabetes, heart disease and certain cancers compared to their neighbors of European and Asian descent, there has been little to no insight into how genetics contribute on top of environmental factors to influence these disparities.

In an attempt to begin rectifying that gap, a USC-led research team has conducted the first study to systematically investigate the genomes of Native Hawaiians and test the components for health risks associated with genetic ancestry. The findings, which appeared in the journal PLoS Genetics, show that, for example, Polynesian ancestry in Native Hawaiians is linked to increased risk of diabetes, heart failure and higher body-mass index, a measure of body fat.

(Charleston Chiang. USC Photo/Ricardo Carrasco III)

Native Hawaiians really have been understudied from a genetic perspective, said corresponding author Charleston Chiang, PhD, an assistant professor of preventive medicine at the Keck School of Medicine of USC and of quantitative and computational biology at USC Dornsife College. Health disparities are a major research emphasis at USC in general, and my team focuses on looking at the genetic component of health risk within geographically diverse populations.

Characterizing Hawaiian Polynesian genetics to understand health risk

Chiang and his colleagues correlated health data (from questionnaire, laboratory measurements, and hospital Medicare claims) and the genetics of 3,940 people who identify as Native Hawaiian from the Multiethnic Cohort Study, a joint project of USC and the University of Hawaii. The research team found that for each 10% increase in estimated Polynesian ancestry, there is on average an 11% increase in risk of heart failure, an 8.6% increase in risk of type2 diabetes and a 0.35 unit increase in body-mass index.

Further studies may be able to identify genetic variants and underlying biological factors specific to Polynesian populations, knowledge that could help reduce these health risks. Chiang also hopes to test a hypothesis outlining a combination of nature and nurture.

For example, its possible that Native Hawaiians had adapted to a traditional diet, and the introduction of the Western diet has led to all kinds of health problems, he said. Thats actually an interaction between their genetics and their environment.

There was a unique challenge for the studys authors to overcome: Researchers focusing on the genetics of people with roots in Europe, Africa and Asia are able to call upon publicly available genomic references for those populations. No such resource exists for Polynesian ancestry. Native Hawaiians are characterized by a mixture of Polynesian, Asian, European and African ancestry. Using the existing references from other populations to run two analyses, the scientists searched for known origins as reflected both across each participants entire genome and location by location along their chromosomes. The research team essentially constructed a genomic model for Polynesian ancestry among Native Hawaiians by identifying a subsample of roughly 150 participants with the least amount of external heritance.

Genomics cant define ethnicity, and biology is not destiny

As should be expected with research charting new territory in biomedical science, the studys authors urge that their findings be interpreted with care and clarity on a few fronts.

Chiang pointed out that race and ethnicity are socially constructed concepts, and distinct from the issues explored in this study that is how certain genes shared among a population contribute to specific health metrics and outcomes. Ethnicity instead is, and should be, defined by genealogical records or how a person self-identifies.

Geneticists should not try to quantize a persons ancestry and use that to define whether that person belongs to a particular ethnic group, he said. While we needed to quantify the proportion of Polynesian ancestry in order to perform our research, we do not want to give the impression that this is a way for people to define their membership in the community based on some arbitrary threshold.

Additionally, Chiang emphasized that the model for Polynesian heritance among Native Hawaiians does not necessarily apply perfectly to populations in other islands such as Samoa.

Perhaps most important, the links between genetics and health revealed in this study should not be construed to mean that being part of any particular population automatically relegates a person to poor health in and of itself.

Genetics is a window into understanding the biology behind these diseases, Chiang said. Genetics does not determine everything, and it doesnt necessarily even amount to the majority of the disparity in risk. I want people to know there are modifiable components to your lifestyle, such as a healthy diet and regular hula dancing, that will absolutely help.

About the studies

The studys co-first authors are Hanxiao Sun, a former masters student in Chiangs research group, and Meng Lin, a former postdoctoral researcher in the group. Other authors are Tsz Fung Chan, Bryan Dinh and Christopher Haiman of USC; Emily Russell and Ryan Minster of the University of Pittsburgh; Take Naseri of the Government of Samoas Ministry of Health; Muagututia Sefuiva Reupena of Lutia i Puava ae Mapu i Fagalele, a nongovernmental organization based in Samoa; Annette Lum-Jones, Lynne Wilkens and Loc Le Marchand of the University of Hawaii; the Samoan Obesity, Lifestyle, and Genetic Adaptations Study Group; and Iona Cheng of the University of California, San Francisco.

The study was supported by the National Cancer Institute (U01CA164973, P01CA168530) and the National Human Genome Research Institute (U01HG007397).

Read the original:
Genetic ancestry linked to diabetes, heart failure and obesity among Native Hawaiians | Keck School of Medicine of USC - USC News

Celebrate the Third Annual Medical Genetics Awareness Week April 13-16, 2021 – PRNewswire

BETHESDA, Md., Feb. 11, 2021 /PRNewswire/ --The third annual Medical Genetics Awareness Week will be celebrated April 1316, 2021. Through Medical Genetics Awareness Week, the American College of Medical Genetics and Genomics (ACMG) aims to promote awareness of the importance of medical genetics professionals on the healthcare team, including medical geneticists, laboratory geneticists, genetic counselors, nurses and physician assistants. The theme of Medical Genetics Awareness Week is "Celebrating the Contributions of the Entire Medical Genetics Team to Patient Care and Public Health."

New for 2021 are high-quality face masks and a Zoom virtual background to help individuals "Share Your Medical Genetics Pride." Participants can share their pictures to social media wearing a Medical Genetics Awareness Week face mask (free for ACMG members) or a Medical Genetics Awareness Week hashtag button; using a new Medical Genetics Awareness Week Zoom virtual background; or displaying a Medical Genetics Awareness Week sticker.

Since 2019, Medical Genetics Awareness Week has brought together people from across the globe to celebrate the important work of medical genetics professionals. Medical Genetics Awareness Week is celebrated to recognize the critical contributions that medical genetics healthcare professionals make in the diagnosis, management and prevention of genetic diseases, and the difference these professionals make in the lives of patients and families. Medical Genetics Awareness Week is also intended to educate other healthcare professionals and students and trainees on who medical geneticists are, how they are trained and what they do in the clinic and laboratory.

Also new for 2021 are themed days that will include a Diversity Day and a Student and Trainee Day. Follow Medical Genetics Awareness Week on social media by searching the #MedicalGeneticsAwareness hashtagand sign up to receive news and updates about Medical Genetics Awareness Week by clicking here. Log in (or create a free ACMG account) and, on the privacy preferences page, opt in to receive news and updates about Medical Genetics Awareness Week.

"Medical genetics and genomics is now deeply wedged into nearly all disciplines of medicine," said ACMG President Anthony R. Gregg, MD, MBA, FACOG, FACMG. "It is a natural extension that we remind the public and all healthcare professionals that those of us who practice medical genetics in clinics, clinical laboratories and research environments work tirelessly and with great enthusiasm. Our singular common goal is to bring accurate genetic information to the bedside that will improve people's lives."

Events related to Medical Genetics Awareness Week will be held during the ACMG Annual Clinical Genetics Meeting A Virtual Experience, April 1316, 2021, but participants don't need to be a meeting registrant to participate in the week's activities. The ACMG Annual Meeting is the largest conference specifically for clinical and laboratory geneticists in the United States. Those interested in collaborating with ACMG to celebrate Medical Genetics Awareness Week, holding their own events or becoming an "ambassador" for medical genetics are invited to email ACMG Communications Coordinator Reymar Santos at [emailprotected]for more information.

"Medical genetics is for all of us," said Max Muenke, MD, FACMG, ACMG'schief executive officer. "I am delighted to celebrate my colleagues in this important field: genetic counselors, laboratory geneticists, medical geneticists, and other allied healthcare professionals who are committed to optimal patient care."

Visit the Medical Genetics Awareness Week web pageson ACMG's website for resources and tips designed to support the week's celebrationsand to join the Medical Genetics Awareness Week email list. When posting on social media, participants are encouraged to tag @TheACMG and include the following hashtags in posts related to Medical Genetics Awareness Week:

#MedicalGeneticsAwareness#IamaMedicalGeneticist#FutureGeneticsProfessional#IamaLabGeneticist#IamaGeneticCounselor#IamaGeneticsPA#IamaNurseinGenetics#IamaGeneticsNP

About the American College of Medical Genetics and Genomics (ACMG) and ACMG Foundation

Founded in 1991, the American College of Medical Genetics and Genomics (ACMG) is the only nationally recognized medical society dedicated to improving health through the clinical practice of medical genetics and genomics and the only medical specialty society in the US that represents the full spectrum of medical genetics disciplines in a single organization. The ACMG is the largest membership organization specifically for medical geneticists, providing education, resources and a voice for more than 2,400 clinical and laboratory geneticists, genetic counselors and other healthcare professionals, nearly 80% of whom are board certified in the medical genetics specialties. ACMG's mission is to improve health through the clinical and laboratory practice of medical genetics as well as through advocacy, education and clinical research, and to guide the safe and effective integration of genetics and genomics into all of medicine and healthcare, resulting in improved personal and public health. Four overarching strategies guide ACMG's work: 1) to reinforce and expand ACMG's position as the leader and prominent authority in the field of medical genetics and genomics, including clinical research, while educating the medical community on the significant role that genetics and genomics will continue to play in understanding, preventing, treating and curing disease; 2) to secure and expand the professional workforce for medical genetics and genomics; 3) to advocate for the specialty; and 4) to provide best-in-class education to members and nonmembers. Genetics in Medicine, published monthly, is the official ACMG journal. ACMG's website (www.acmg.net) offers resources including policy statements, practice guidelines, educational programs and a 'Find a Genetic Service' tool. The educational and public health programs of the ACMG are dependent upon charitable gifts from corporations, foundations and individuals through the ACMG Foundation for Genetic and Genomic Medicine.

Kathy Moran, MBA[emailprotected]

SOURCE American College of Medical Genetics and Genomics

http://www.acmg.net

See more here:
Celebrate the Third Annual Medical Genetics Awareness Week April 13-16, 2021 - PRNewswire